Tier 2 — strong

The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity

Almudena Perez, Susana Gonzalez-Manzano, Rosario Jimenez, Rocío Perez-Abud, Jose M Haro, Antonio Osuna, Celestino Santos-Buelga, Juan Duarte, Francisco Perez-Vizcaino
Pharmacological research 2014 89:11

Bibliography

PubMed
PMID 25076013
DOI
10.1016/j.phrs.2014.07.005
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover experiment
ModelHuman intervention research
Sample15 healthy volunteers
InterventionQuercetin 200 mg or 400 mg
DurationSingle doses on separate weeks; vascular measurements through 5 hours
EndpointsBlood pressure; Exposure and pharmacokinetics

What the study showed, in plain terms

Published in 2014, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover experiment. Sample/model: 15 healthy volunteers. The exposure or intervention was Quercetin 200 mg or 400 mg. Follow-up or treatment period: Single doses on separate weeks; vascular measurements through 5 hours.

Brachial artery diameter increased at 5 hours, while blood pressure and circulating nitric oxide metabolites did not change.

Small acute physiological study, not evidence of sustained antihypertensive treatment or cardiovascular event prevention.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Brachial artery diameter increased at 5 hours, while blood pressure and circulating nitric oxide metabolites did not change.
  • The recorded outcome domains were Blood pressure; Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 200 mg or 400 mg; Single doses on separate weeks; vascular measurements through 5 hours.

What this study can and cannot tell us

  • Small acute physiological study, not evidence of sustained antihypertensive treatment or cardiovascular event prevention.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology